Medicinova Stock Price, News & Analysis

MediciNova completed a $20M private placement and formed a partnership with BARDA to develop MN-166 for acute lung injury from chlorine gas. The company received $4M in milestone payments from Genzyme and maintains a robust cash balance of $76M to support late-stage programs. Financial results for Q1 2021 include $4M in revenue and a net loss of just $0.2M, an improvement from the previous year. Key clinical trials are ongoing for MN-166 in ALS and COVID-19, alongside preparations for a Phase 2 study in NASH.

MediciNova, Inc. announced receiving a Notice of Intention to Grant from the European Patent Office for a patent covering the combination of MN-166 (ibudilast) and riluzole to treat amyotrophic lateral sclerosis (ALS). This patent is expected to expire no earlier than November 2035 and includes various dosing regimens. The company is currently conducting a Phase 3 clinical trial in the U.S. and Canada for this combination, which has received orphan-drug and fast-track designations from the FDA. MediciNova aims to enhance the treatment landscape for ALS, affecting approximately 16,000 patients in the U.S.

MediciNova (NASDAQ:MNOV) announced receipt of two milestone payments totaling $4 million from Genzyme, a Sanofi subsidiary. These payments are due to successful achievements in clinical development milestones concerning a gene therapy product utilizing AAV vector technology. This development emphasizes MediciNova's strategic focus on treatments for unmet medical needs, including neurological disorders and fibrotic diseases. The company continues to advance its pipeline with products like MN-166 and MN-001.

MediciNova has announced participation in a fireside chat at the B. Riley Neuroscience Conference on April 29, 2021, at 1:30 p.m. ET. CEO Yuichi Iwaki and VP Geoffrey O'Brien will discuss MN-166 (ibudilast), a treatment for neurological conditions including ALS and multiple sclerosis. MN-166 inhibits pro-inflammatory cytokines and promotes neurotrophic factors, backed by promising preclinical and clinical trial results. The company will also be available for one-on-one meetings during the conference, allowing investors to engage directly.

MediciNova, a biopharmaceutical company trading on NASDAQ under the symbol MNOV, will participate in the UBS Global Healthcare Virtual Conference from May 24-26, 2021. Key executives, including Yuichi Iwaki, MD, PhD, President, and Geoffrey O'Brien, JD/MBA, Vice President, will hold one-on-one meetings with investors. MediciNova is focused on developing novel therapeutics for unmet medical needs, targeting neurological disorders and fibrotic diseases. For more details, visit medicinova.com.

MediciNova, Inc. has announced a partnership with BARDA to repurpose its drug MN-166 (ibudilast) as a medical countermeasure against chlorine gas-induced lung damage. This collaboration falls under BARDA's ReDIRECT program, which provides funding for proof-of-concept studies in preclinical models. MN-166 has shown efficacy in reducing pulmonary injury in animal models and has been administered to over 800 clinical trial participants. The drug is also in late-stage development for several neurological disorders and COVID-19-related ARDS.

MediciNova, a biopharmaceutical company trading as MNOV, announced its participation in the Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. CEO Yuichi Iwaki and VP Geoffrey O'Brien will hold one-on-one investor meetings, facilitated by Maxim Group. MediciNova focuses on developing small-molecule therapeutics for diseases such as progressive multiple sclerosis and substance dependence, with key products including MN-166 and MN-001. The conference will feature discussions and presentations from various issuers, enhancing visibility for emerging growth companies.

MediciNova, Inc. has announced the discontinuation of its SARS-CoV-2 vaccine development due to the presence of established vaccines and those in advanced development. This strategic decision aims to redirect resources toward other critical programs with significant unmet medical needs and market potential. MediciNova's focus will now remain on therapies like MN-166 for neurological disorders and MN-001 for treating fibrotic diseases, ensuring its alignment with larger medical opportunities.

MediciNova, a biopharmaceutical company trading under NASDAQ:MNOV, has completed a private placement of $20 million in stock to 3D Opportunity Master Fund. The funding will support three key initiatives: starting a pivotal clinical trial for MN-166 (ibudilast) in glioblastoma, developing an intravenous formulation of MN-166 for ALS patients, and initiating a Phase 2 trial for MN-001 (tipelukast) in NASH. The company aims to address unmet medical needs in various neurological and fibrotic diseases.